Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval ... reach the brain," according to the FDA. It will use Journavx as its brand name. GET FOX BUSINESS ON THE ...

The U.S. Food and Drug Administration announced that it has approved a new non-opioid painkiller pill from Vertex Pharmaceuticals called suzetrigine, which is being sold under the name Journavx.

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a listen-only mode. [Operator instructions] Please note, this event is being ...

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. Vertex ...

Vertex Pharmaceuticals (NASDAQ ... Last Thursday, the agency approved Vertex's Journavx in treating adults with moderate-to-severe acute pain. Unsurprisingly, investors reacted positively to ...

Journavx is a first-in-class non-opioid ... in annual sales by 2030 would be a step in the right direction for Vertex Pharmaceuticals but this wouldn't be a transformative contribution.